Eli Lilly Launches Mounjaro KwikPen in Canada to Aid Type 2 Diabetes Management
Eli Lilly and Company has announced the Canadian release of the Mounjaro® (tirzepatide) KwikPen, a novel injectable medication designed to assist adults with type 2 diabetes in managing blood sugar levels. This development offers a new therapeutic option for those seeking effective diabetes management solutions.
Mounjaro is the first and only dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes treatment. By activating both GIP and GLP-1 receptors, Mounjaro enhances insulin secretion and inhibits glucagon release, leading to improved blood sugar control.
The Mounjaro KwikPen is a user-friendly, pre-filled injection device intended for once-weekly subcutaneous administration. It is available in multiple dosages, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL injection, allowing healthcare providers to tailor treatment to individual patient needs.
Health Canada approved the Mounjaro KwikPen on September 24, 2024, under Drug Identification Number (DIN) 02551977.
Eli Lilly emphasizes the importance of obtaining Mounjaro through authorized healthcare providers and pharmacies to ensure patient safety. The company has recently issued warnings about the dangers of counterfeit versions of its medications, underscoring the need for vigilance in sourcing prescription drugs.
For more information about Mounjaro, including prescribing information and patient resources, visit Eli Lilly’s official website.